switching between glp-1 agonists ada Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review Why does GLP‐1 agonist combined

But with that popularity comes the question: what to expect if your patients have to stop the medication

They differ in potency, duration of action, and specific receptor binding characteristics, but theyre fundamentally doing the same thing: mimicking and amplifying your bodys natural GLP-1 signals

doi:10.1016/j.bioorg.2020.104492 17

Dalton M, Buckland N, Blundell J

The risk of cholelithiasis among different GLP1-RAs Table 4 showed the overall relative risk of cholelithiasis was 1.2, 1.3, and 1.4 in liraglutide, dulaglutide, and semaglutide versus control with number needed to harm of 17.25, 14.69, and 10.96, respectively

In some patients, it shows a weight-reducing effect of nearly 30 percent, a level expected when conducting obesity metabolic surgery. Park added all these show obese people can reduce weight to a certain extent without surgeries